| Literature DB >> 31626715 |
Raquel Blazquez1,2, Eva Rietkötter2, Britta Wenske1,2, Darius Wlochowitz3, Daniela Sparrer1, Elena Vollmer1, Gunnar Müller1, Julia Seegerer1, Xueni Sun4, Katja Dettmer4, Alonso Barrantes-Freer5,6, Lena Stange7, Kirsten Utpatel8, Annalen Bleckmann2,9, Hannes Treiber2,10, Hanibal Bohnenberger11, Christof Lenz12,13, Matthias Schulz2, Christian Reimelt14, Christina Hackl15, Marian Grade16, Deram Büyüktas2, Laila Siam17, Marko Balkenhol18, Christine Stadelmann5, Dieter Kube2, Michael P Krahn19, Martin A Proescholdt20, Markus J Riemenschneider7, Matthias Evert8, Peter J Oefner4, Chistoph A Klein14,21, Uwe K Hanisch5, Claudia Binder2, Tobias Pukrop1,2.
Abstract
More than half of all brain metastases show infiltrating rather than displacing growth at the macro-metastasis/organ parenchyma interface (MMPI), a finding associated with shorter survival. The lymphoid enhancer-binding factor-1 (LEF1) is an epithelial-mesenchymal transition (EMT) transcription factor that is commonly overexpressed in brain-colonizing cancer cells. Here, we overexpressed LEF1 in an in vivo breast cancer brain colonization model. It shortened survival, albeit without engaging EMT at the MMPI. By differential proteome analysis, we identified a novel function of LEF1 as a regulator of the glutathione (GSH) system, the principal cellular redox buffer. LEF1 overexpression also conferred resistance against therapeutic GSH depletion during brain colonization and improved management of intracellular ROS. We conclude that besides EMT, LEF1 facilitates metastasis by improving the antioxidative capacity of epithelial breast cancer cells, in particular during colonization of the brain parenchyma.Entities:
Keywords: LEF1; ROS; brain metastasis; glutathione; metastatic colonization
Mesh:
Substances:
Year: 2019 PMID: 31626715 DOI: 10.1002/ijc.32742
Source DB: PubMed Journal: Int J Cancer ISSN: 0020-7136 Impact factor: 7.396